More than 10,000 Aetna members invited to use mobile app with artificial intelligence from Welldoc and LifeScan Inc.
Hartford, CT and Columbia, MD – Today, Healthagen, an Aetna business unit within CVS Health, and Welldoc, in collaboration with LifeScan Inc., announced details of a study to evaluate the use and potential health benefits of OneTouch Reveal® Plus. The mobile and web coaching tool is for adults with type 2 diabetes. The study will evaluate changes in specific health outcomes among individuals who participate in the tool’s tailored virtual coaching and engagement.
“We are pleased to work on a study with Healthagen to not only evaluate how well the technology can support individuals living with type 2 diabetes today, but to also understand what we can improve upon in the future,” says Welldoc President and CEO Kevin McRaith.
In 2018, Welldoc and LifeScan Inc., introduced OneTouch Reveal® Plus as a benefit offering for health insurers and plan sponsors. The product integrates WellDoc’s BlueStar® digital therapeutic technology with LifeScan’s OneTouch Verio Flex® blood glucose monitoring system. OneTouch Reveal® Plus offers real-time coaching based on an individual’s unique profile and treatment plan.
While factors such as diet, exercise, and medication are key to managing blood sugar levels, no single formula exists that works for everyone. The app gets to know each user and is always learning and adapting to optimize the coaching experience. The coaching guides users on ways to treat high or low blood sugar in the moment as well as how to resolve patterns over time.
Healthagen offers powerful analytical capabilities to test the practical application of health care products and services among Aetna members. Between November 2018 and January 2019, more than 10,000 Aetna commercial members with type 2 diabetes were invited to participate in this study. Participants agreed to use the OneTouch Reveal® Plus technology for six months. During this time, Healthagen will track how well and how long members take their medicines (if prescribed), average blood sugar levels (HbA1c lab values), incidence of significantly high or low blood sugar levels (hypoglycemia and hyperglycemia), doctor visits, hospital stays and emergency room visits. These findings can be correlated to overall health care costs, medical resource utilization and outcomes associated with type 2 diabetes management among participants.
“In addition to historical data, this study incorporates information from active, clinically qualified participants. The resulting insights will highlight the potential value and opportunities of the OneTouch Reveal® Plus technology. The study may contribute to helping providers and their patients manage their diabetes and achieve overall health goals,” said Healthagen President, Van Crocker.
Healthagen offers analytical and advisory services that meet the market and clinical challenges faced by pharmaceutical, biotech, and medical device companies. Healthagen uses real-world data, advanced technologies, and professional know-how to illuminate therapeutic and economic value. We offer collaborative resources across Aetna to enable forward looking research into real-world outcomes and the realities of therapeutic use in genuine clinical settings. Healthagen has collaborated with new technology makers to advance therapies that improve care and lower cost while providing valuable business insight in the healthcare space www.healthagen.com.
Welldoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. The Company’s groundbreaking technology helps guide individuals through the complicated journey of living with chronic diseases, with a goal of helping them self-manage their conditions, while connecting them to their own healthcare team. By utilizing Welldoc’s digital therapeutic solutions, payers, employers and healthcare systems can streamline their resources by focusing on a digital health solution to help better manage their populations living with multiple and costly chronic diseases. Welldoc is based on a life science business model—having conducted multiple randomized clinical trials resulting in more than 40 peer-reviewed publications. IBM Watson Health™ conducted an innovative economic analysis for Welldoc using the MarketScan® Commercial Claims and Encounters Database and the MarketScan® Medicare Supplemental and Coordination of Benefits Database demonstrating an opportunity to save a range of $254 to $271 per user per month with the use of the flagship BlueStar® digital therapeutic. Welldoc has a solid foundation in the development of solutions for the management of diabetes and is rapidly creating other chronic disease solutions. This year, Welldoc secured a patent for the Software Engine Technology that powers BlueStar. Notably, this is the Company’s tenth issued patent. For more information, visit www.welldoc.com.